Scientists in Japan have found that beta-blockers may be able to block the effects of Genshen-induced high blood pressure, a condition that can cause kidney damage and ultimately lead to death.
The study, led by researchers at Kobe University in Japan, is the first to demonstrate that beta blockers can prevent the effects caused by Genshihin-induced elevated blood pressure in rats.
The findings, published in the journal PLOS One, may have implications for the treatment of GDS.
Beta blockers have a broad range of potential applications for treating GDS, but researchers say that the ability to block Genshit-induced blood pressure is crucial.
The researchers found that mice lacking beta-blocking protein, or BAP, showed signs of slowing down their metabolic rate and slowing their ability to metabolize blood glucose, which is important for managing blood pressure.
Beta blocking proteins are found in some types of cancer and other diseases, including heart disease.
The protein is also found in beta-carotene, a nutrient found in red and green vegetables and in the brain.
“Our findings show that beta blocking protein is a valuable anti-inflammatory drug target for the Genshakine treatment,” said Dr. Hideo Morita, one of the lead researchers of the study.
“However, its use for treating the GDS has been limited due to the side effects associated with beta blocking.”
The Japanese researchers found beta-Blockers in mice lacking the BAP gene, but also found beta blockers in mice that lacked the gene for the protein.
Beta-blocker therapy is a new type of anti-hypertensive treatment that uses beta-subunit blockers.
The drugs are given orally to treat high blood sugar, high cholesterol and diabetes.
“We know that beta blockers inhibit beta-cells in the liver and are a good treatment for the development of Gds,” Morita said.
“We hope that the drug beta-blocks will have an equally good effect for treating other diseases.”
The study found that BAP-deficient mice showed a decrease in the production of beta-actin, a protein that is produced by the liver, when they were given beta blockers.
“Beta-actins are important in the development and function of the liver,” said lead researcher Professor Masaki Yamamoto, of Kobe University.
“But BAP deficiency has also been implicated in the progression of liver disease.”
The researchers hope that beta blocker therapy could help to treat patients who are not able to use beta blockers due to their age, liver disease or other conditions.
“It would be a very interesting drug to try in patients who have no other treatment options,” Morini said.